# A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

> **NCT00238797** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 36 (—)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00238797
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 36 (—)
- **Last updated:** 2011-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238797, "A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00238797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*